Versions

US Court Confirms FDA’s Decision to Ban Compounded Versions of Ozempic and Wegovy

by

A federal judge in New York has supported a U.S. Food and Drug Administration decision that prohibits the compounding of alternatives to the diabetes medication Ozempic and its weight-loss counterpart, Wegovy. The ruling comes amid soaring demand for these drugs, which have gained popularity for their effectiveness in managing weight. The case arose when a group of pharmacies sought to produce compounded versions of these medications, which are manufactured by Novo Nordisk. These compounded alternatives would allow pharmacists to create custom formulations for patients, yet the FDA argued that such practices may pose risks of … Read more

Federal Judge Upholds Ban on Generic Versions of Lilly’s Breakthrough Weight Loss Medication

by

Indianapolis — A federal judge in Indiana has refused to issue an injunction that would have halted a ban on unauthorized copies of a widely popular weight-loss medication produced by Eli Lilly and Company. This decision keeps in place the enforcement against the manufacturing and distribution of generic versions of the pharmaceutical giant’s patented drug. This ruling directly impacts a number of pharmaceutical manufacturers who have been accused by Eli Lilly of infringing on its patents by replicating Mounjaro, a drug which has shown significant efficacy in both weight management and the treatment of type … Read more